Rocklatan for Glaucoma

This trial tests a new treatment for certain types of glaucoma, an eye condition that can lead to vision loss. It compares two treatments: Rocklatan, a combination of two drugs, and latanoprost, a single drug. The trial aims to determine which treatment better reduces eye pressure. Suitable participants have mild to moderate open-angle glaucoma in both eyes and currently use three eye pressure-lowering medications, including a prostaglandin analog. As a Phase 4 trial, this research seeks to understand how an already FDA-approved and effective treatment can benefit more patients.

Yes, participants must stop taking their current glaucoma medications for a washout period (time without taking certain medications) before the baseline visit.

Research has shown that Rocklatan, a combination of netarsudil and latanoprost, is generally safe for treating glaucoma. Studies have found that this combination effectively lowers eye pressure over a year.

In one study, 60% of patients reduced their eye pressure to 16 mm Hg or lower, demonstrating its effectiveness. Another study confirmed the drug's safety, with no serious side effects reported over a year.

Rocklatan is unique because it combines two active ingredients: netarsudil and latanoprost. Most glaucoma treatments, like latanoprost, focus on lowering eye pressure by increasing the outflow of fluid. However, Rocklatan not only enhances fluid outflow but also reduces fluid production, offering a dual-action approach. Researchers are excited about Rocklatan because this combination could potentially improve eye pressure control more effectively than using latanoprost alone.

Research has shown that Rocklatan, a combination of netarsudil and latanoprost, effectively lowers eye pressure in people with glaucoma. This trial will compare Rocklatan with latanoprost alone. Rocklatan reduces eye pressure by 1.3 to 3.0 mm Hg more than using either netarsudil or latanoprost alone. In one study, 60% of patients using Rocklatan achieved an eye pressure of 16 mm Hg or lower, marking a significant improvement. Additionally, after 3 months, 43.5% of patients using Rocklatan reached an eye pressure of 15 mm Hg or less. These findings suggest that Rocklatan is a strong option for managing high eye pressure in glaucoma.¹³⁶⁷⁸